Use of statins for the treatment of spontaneous intracerebral hemorrhage: Results of a pilot study

Zentralblatt fur Neurochirurgie

Volumn 70, Issue 1, 2009, Pages 15-20

  Tapia Perez, H ^a,b   Sanchez Aguilar, M ^a   Torres Corzo, J G ^b   Rodriguez Leyva, I ^b   Gonzalez Aguirre, D ^a   Gordillo Moscoso, A ^a   Chalita Williams, C ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

Author keywords

Hemorrhage; Intracerebral; Neuroprotection; Statins

Indexed keywords

ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANNITOL; ROSUVASTATIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROL GROUP; CONTROLLED STUDY; DRUG USE; FEMALE; GLASGOW COMA SCALE; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INTUBATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OUTCOME ASSESSMENT; PILOT STUDY; PNEUMONIA; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK; SEX; SUBARACHNOID SPACE; THERAPY EFFECT;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CEREBRAL HEMORRHAGE; FEMALE; FLUOROBENZENES; GLASGOW COMA SCALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRIMIDINES; RETROSPECTIVE STUDIES; SAMPLE SIZE; STROKE; SULFONAMIDES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84879240906     PISSN: 00444251     EISSN: 14389746     Source Type: Journal    
DOI: 10.1055/s-0028-1082064     Document Type: Article

References (50)

1. Agarwal R. Effects of statins on renal function. Am J Cardiol 2006; 97: 748-755
2. Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559
3. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M, American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults 2007. Stroke 2007; 38: 2001-2023
4. Browne RH. On the useofa pilot simple for sample size determination. Statistics in Medicine 1995; 14: 1933-1940
5. Fletcher B, Berra K, Ades P, Braun LT, Burke LE, Durstine JL, Fair JM. Fletcher GF, Goff D, Hayman LI, Hiatt WR, Miller NH, Krauss R, Kris-Etherton P, Stone N, Wilterdink J, Winston M. Managing abnormal blood lipids: a collaborative approach. Circulation 2005; 112: 3184-3209
6. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help in caring for my patients? Evidence Based Medicine Working Group. JAMA 1994; 271: 59-63
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
8. Iso H, Jacobs Jr DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989; 320: 904-910
9. Italian Acute Stroke Study Group. Haemodilution in acute stroke: results of the Italian haemodilution trial. Lancet 1988; 1: 318-321
10. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006; 17; 97: 44C-51C
11. Jones PH, Davidson MH, Stein EA, Bays HE, MacKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatain across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-160
12. Jonsson N, Asplund K. A pilot case-referent study: Does pretreatment with statins improve clinical outcome after stroke? Stroke 2001; 32: 1112-1115
13. Jung KH, Chu K, Jeong SW, Han SY, Lee ST, Kim JY, Kim M, Roh JK HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004; 35: 1744-1749
14. Juvela S, Kase CS. Advances in intracerebral hemorrhage management. Stroke 2006; 37: 301-304
15. Kasner SE, Chalela JA, Luciano JM, Cucchiara BL, Raps EC, MacGarvey ML, Conroy MB, Localio AR. Reliability and validity of estimating the NIH stroke scale from medical records . Stroke 1999; 30: 1534-1537
16. Kilic U, Bassetti CL, Kilic E, XingH, Wang Z, Hermann DM. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2 . Neuroscience 2005; 134: 901-906
17. Lee SH, Bae HJ, Yoon BW , Kim H, Kim DE, Roh JK. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions . Stroke 2002; 33: 2845-2849
18. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357
19. Lynch JR, Wang H, MacGirt MJ, Floyd J, Friedman AH, Coon AL, Blessing R, Alexander MJ, Graffagnino C, Warner DS, Laskowitz DT. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial . Stroke 2005; 36: 2024-2026
20. Martí-Fàbregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvís R, Cocho D, Roquer J, Rodríguez A, García MD, Molina-Porcel L, Díaz-Manera J, Martí-Vilalta JL. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35: 1117-1121
21. Mayer SA, Brun NC, Broderick J, Davis SM, Diringer MN, Skolnick BE, Steiner T, United States NovoSeven ICH Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care 2006; 4: 206-214
22. MacGirt MJ, Blessing R, Alexander MJ, Nimjee SM, Woodworth GF, Friedman AH, Graffagnino C, Laskowitz DT, Lynch JR. Risk of cerebral vasopasm after subarachnoid hemorrhage reduced by statin therapy: A multivariate analysis of an institutional experience. J Neurosurg 2006; 105: 671-674
23. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365: 387-397
24. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005; 36: 1298-1300
25. Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Carhuapoma JR . An association of prior statin use with decreased perihematomal edema. Neurocrit Care 2008; 8: 13-18
26. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care 2008; 8: 6-12
27. Parra A, Kreiter KT, Williams S, Sciacca R, Mack WJ, Naidech AM, Commichau CS, Fitzsimmons BF, Janjua N, Mayer SA, Connolly Jr ES. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: A matched controlled cohort study. Neurosurgery 2005; 56: 476-484
28. Poungvarin N, Bhoopat W, Viriyavejakul A, Rodprasert P, Buranasiri P, Sukondhabhant S, Hensley MJ, Strom BL. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 1987; 316: 1229-1233
29. Ali M. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
30. Ruiz-Sandoval JL, Ortega-Alvarez L, Garcia-Navarro V, Romero-Vargas S, Gonzalez-Cornejo S. Intracerebral hemorrhage in a referral hospital in the central-western of Mexico. Rev Neurol 2005; 40: 656-660
31. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N EnglJ Med 1996; 335: 1001-1009
32. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718
33. Scott EK. Clinical interpretation and use of stroke scales . Lancet Neurol 2006; 5: 603-612
34. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Maclnnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158
35. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg 2004; 101: 104-107
36. Shepherd J, Cobbe SM, Ford l, lsles CG , Lorimer AR, MacFarlane PW, MacKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307
37. Shook SJ, Gupta R, Vora NA, Tievsky AL, Katzan I, Krieger DW. Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. J Neuroimaging 2006; 16: 341-346
38. Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, Cremonesi B, Paoletti R, Tremoli E. Rosuvastatin, but not simvastatin, provides endorgan protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 2005; 25: 598-603
39. Staffa JA, ChangJ, Green L. Cerivastatin and reports of fatal rhabdomyolysis [letter]. N EnglJ Med 2002; 346: 539-540
40. Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, Rodriguez-Leyva I, Herrera-Gonzalez LB. Statins and brain protection mechanisms . Rev Neurol 2007; 45: 59-64
41. Telleria-Diaz A. Management and predictors in patients with spontaneous intracerebral hemorrhage. Rev Neurol 2006; 42: 341-349
42. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with statins on cerebral autoregulation in patients after aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006 ; 21: E10
43. Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute pravastatin treatment on intensity of rescue therapy, length of in-patient stay, and 6-month outcome in patients after aneu- rysmal subarachnoid hemorrhage. Stroke 2007; 38: 1545-1550
44. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol 2005; 96 (suppl): 69F-75F
45. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T, MlRACL Study lnvestigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690-1695
46. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E, PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2006; 47: 472
47. Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Szaflarski JP, Gebel JM, Pancioli AM, Jauch EC, Schneider A, Kleindorfer D, Broderick JP. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004; 35: 1360-1364
48. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program . Stroke 1989; 20: 1460-1465
49. Yoon SS, Dambrosia J, Chalela J, Ezzeddine M, Warach S, Haymore J, Davis L, Baird AE. Rising statin use and effect on ischemic stroke outcome. BMC Med 2004; 2: 4
50. Yu YL, Kumana CR, Lauder IJ, Cheung YK, Chan FL, Kou M, Chang CM, Cheung RT, Fong KY. Treatment of acute cerebral hemorrhage with intravenous glycerol: a double-blind, placebo-controlled, randomized trial. Stroke 1992; 23: 967-971